Trials on the use of dabrafenib in other solid tumors including BRAF V600E/K-mutatedcolorectal cancer, BRAF V600E-mutated non–small cell lung cancer, and BRAF V600E-mutated thyroidcancer are also ongoing. This evidence concerns the gene BRAF and lung cancer.